(NIAID) trial now suggest the tide could be turning. Protégé investigator Kevan Herold, of Yale University, and his colleagues carried out a follow‐up trial of teplizumab after noting a larger treatment effect associated with younger age, recruitment from the United States and early treatment in the Protégé data. Their NIAID-sponsored Phase II study — carried out in younger patients in North America — has now met its primary end point, giving a new boost to the anti‐CD3 hypothesis (Diabetes http://dx.doi.org/10.2337/db13‐0345; 2013). The authors point out that type 1 diabetes is relatively easy to diagnose in North Americans and individuals there tend to have lower insulin requirements, lower glycated haemoglobin (HbA1c) levels and lower incidence of diabetic ketoacidosis, potentially explaining the geographical success. The team also found that metabolic and immunological features — including low HbA1c and insulin use at the time of A comeback for anti‐CD3s in type 1 diabetes?